CLINICAL DEVELOPMENT IN ONCOLOGY
Oncology leads trials for 2023 with more than 52% of trials in Phase II
This figure represented a slight increase from 2022 for oncology. GLOBALDATA HEALTHCARE
Credit: Yuri A via
Shutterstock.com. A
ccording to GlobalData’s Clinical Trials Database, among clinical trials for 2023, Phase II led with 41.0% of trials.
This was followed by Phase I (26.6%), Phase III (17.0%), and Phase IV (15.4%). Oncology had the highest number of clinical trials in Phase I and II in 2023 while the central nervous system had the most Phase III and IV trials, the same as it was in 2022. Due to the differences in the absolute trial numbers in various therapy areas, the proportions of trials in different phases within each therapy area have been estimated to show an accurate picture of the phase-wise distribution of trials within and across multiple therapy areas.
Although oncology had the highest number of trials within Phase I, metabolic disorders had the largest proportion of Phase I trials with 36.5%, followed by cardiovascular (34.9%) and immunology (33.4%). Oncology had the greatest proportion of Phase II trials, with 52.6% of the total trials, representing a slight increase from 2022. This could be due to more oncology drugs being approved once in Phase II, possibly because the trial landscape is returning to normal after the Covid-19 pandemic. Dermatology had the highest proportion of Phase III clinical trials (22.9%) while cardiovascular had the highest proportion of Phase IV trials (20.7%).
Clinical Trials in Oncology | 15
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44
